Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Dianthus Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.7 million for Q2 2023.

• On a quarterly basis, Change in Accured Expenses fell 169.82% year-over-year to -$1.7 million in Q2 2023; TTM through Jun 2023 was -$2.6 million, a 48.18% decrease from a year earlier, with the FY2022 full-year figure at $973000.0, up 535.95% from the prior year.
• Change in Accured Expenses grew to -$1.7 million in Q2 2023 per DNTH's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.7 million in Q4 2019 and bottomed at -$3.3 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is -$260500.0 (2020), against an average of -$135444.4.
• Across the five-year window, Change in Accured Expenses soared 643.89% in 2019 and tumbled 288.71% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.7 million in 2019, then tumbled by 93.13% to $255000.0 in 2020, then tumbled by 271.76% to -$438000.0 in 2021, then surged by 446.8% to $1.5 million in 2022, then sank by 210.66% to -$1.7 million in 2023.
• Per Business Quant, the three latest DNTH Change in Accured Expenses figures stand at -$1.7 million (Q2 2023), -$3.3 million (Q1 2023), and $1.5 million (Q4 2022).